ReviewMolecular cancer2026

Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities.

Junxin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.